Insight Molecular Diagnostics Inc. (7OC0)

Overview

Insight Molecular Diagnostics Inc. is a pioneering precision diagnostics company dedicated to the development and commercialization of sophisticated molecular diagnostic tests tailored for both clinical and research applications. The company, founded in 2009 and headquartered in Nashville, emphasizes a core focus on transplant medicine and oncology. By addressing critical unmet needs in patient care, Insight Molecular Diagnostics plays a transformative role in enhancing patient outcomes through personalized and real-time interventions. Their innovative approach not only aids in patient monitoring but also supports advancements in in-vitro diagnostics and biomarker discovery through collaboration with leading industry professionals such as Bio-Rad Laboratories.

Products and Services

• VitaGraft Kidney Test: A blood-based diagnostic assay designed to monitor kidney transplant rejection by detecting donor-derived cell-free DNA. This innovative test enables healthcare providers to assess the health of transplanted organs in a timely manner, potentially leading to better patient outcomes.
• VitaGraft Liver Test: Similar to the VitaGraft Kidney Test, this assay focuses on liver transplants. It utilizes cutting-edge blood-based detection methods to monitor for potential organ rejection, ensuring that patients receive the necessary interventions promptly.
• GraftAssure Suite: Leveraging droplet digital PCR technology, this suite of tests offers highly sensitive monitoring capabilities for transplant patients. It aids clinicians in determining the likelihood of transplant rejection, fostering proactive measures in patient management.
• DetermaCNI: Targeting the oncology sector, this blood-based assay detects early progression of cancer after a single cycle of treatment. DetermaCNI empowers oncologists with critical information that can influence treatment decisions and improve patient prognosis.
• DetermaIO: This innovative test predicts a patient’s response to immunotherapies by evaluating factors within the tumor microenvironment. DetermaIO is poised to inform treatment plans, enabling clinicians to tailor their approaches based on predicted outcomes.
• Biomarker Discovery: Insight Molecular Diagnostics actively engages in the discovery of biomarkers, facilitating the identification of novel diagnostic targets that can further enhance precision medicine applications in various health conditions.
• Assay Development: The company specializes in the development of custom assays tailored to the needs of research and clinical applications, thereby enhancing diagnostic capabilities in the healthcare field.
• Clinical Trial Support: By collaborating with pharmaceutical partners, Insight Molecular Diagnostics supports clinical trials aimed at validating the efficacy of new diagnostics. This service is essential for advancing innovative treatment options across different therapeutic landscapes.